Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Show more

66 Hudson Boulevard East, New York, NY, 10001-2192, United States

Drug Manufacturers - General
Healthcare

Market Cap

155.9B

52 Wk Range

$20.92 - $27.94

Previous Close

$27.41

Open

$27.38

Volume

63,499,429

Day Range

$26.80 - $27.54

Enterprise Value

206.3B

Cash

13.6B

Avg Qtr Burn

N/A

Insider Ownership

0.10%

Institutional Own.

67.74%

Qtr Updated

12/31/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
TALA + enzalutamide Details
Cancer, Prostate cancer, Castration-resistant prostate cancer

Approved

Update

Approved

Update

Approved

Update

Approved

Quarterly sales

Oxbryta (Voxelotor) Details
SCD (Sickle Cell Disease)

Approved

Quarterly sales

Approved

Quarterly sales

ELREXFIO (elranatamab) Details
Cancer, Multiple myeloma

Approved

Quarterly sales

TUKYSA (Tucatinib) Details
Solid tumor/s, Cancer, Metastatic colorectal cancer, Colorectal cancer

Approved

Quarterly sales

BRAFTOVI® + cetuximab & mFOLFOX6 Details
Metastatic colorectal cancer

Approved

Quarterly sales

ABRYSVO Details
Respiratory syncytial virus, Respiratory virus

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

PADCEV® Details
Urothelial carcinoma

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

LORBRENA® Details
Cancer, Lung cancer, Non-small cell lung carcinoma

Approved

Quarterly sales

ABRYSVO Details
Respiratory syncytial virus, Respiratory virus

Approved

Quarterly sales

Approved

Quarterly sales

VELSIPITY Details
Ulcerative colitis

Approved

Quarterly sales

Approved

Quarterly sales

Aztreonam-Avibactam (ATM-AVI) Details
Pneumonia, Bacterial infection, Intra-abdominal infections

NDA

Submission

Phase 3

Data readout

IBRANCE (palbociclib) Details
Cancer, Breast cancer

Phase 3

Data readout

Phase 3

Data readout

Talzenna/Talazoparib + Xtandi/Enzalutamide (BMN 673 + MDV3100) (PARP Inhibitor) Details
HRR Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Phase 3

Data readout

Sasanlimab + BCG Details
Non-muscle invasive bladder cancer

Phase 3

Update

Phase 3

Update

TUKYSA (Tucatinib) combo Kadcyla Details
HER2+ Metastatic Breast Cancer

Phase 3

Update

Phase 3

Update

Phase 3

Initiation

Ponsegromab Details
Cancer, Cancer cachexia

Phase 3

Initiation

Troriluzole Details
Obsessive compulsive disorder

Phase 2/3

Data readout

Phase 2/3

Initiation

Phase 2/3

Initiation

Phase 2b

Data readout

Phase 2

Data readout

ADCETRIS® + pembrolizumab Details
Solid tumor/s, Melanoma, Non-small cell lung carcinoma

Phase 2

Data readout

Phase 2

Update

Phase 2

Update

Atirmociclib (CDK4 Inhibitor) Details
HR-Positive, HER2-Negative Advanced Or Metastatic Breast Cancer

Phase 2

Update

Phase 2

Update

Phase 2

Update

Failed

Discontinued

Troriluzole Details
Spinocerebellar Ataxia

Failed

Discontinued

Verdiperstat Details
Multiple System Atrophy

Failed

Discontinued

Troriluzole Details
Alzheimer's disease

Failed

Discontinued

Verdiperstat Details
Amyotrophic lateral sclerosis

Failed

Discontinued

Danuglipron Details
Obesity, Type 2 diabetes

Failed

Discontinued